NAMS at 30: Making Menopause Mainstream
During 2019, there were many highlights, accomplishments, and changes for The North American Menopause Society (NAMS). These accomplishments are only possible through the support and generosity of our members, our donors, our grantors, and our Central Office Staff.

The 2019 Annual Meeting was a celebration of the Society’s 30th anniversary. The meeting was held in Chicago with the theme NAMS at 30: Making Menopause Mainstream. The meeting was outstanding, thanks to the Scientific Program Chair, Dr. Marla Shapiro; her hardworking Scientific Program Committee; and all the excellent speakers. As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), NAMS continues to offer education credit for its educational programs.

The 2019 Pre-Meeting Symposium addressed Perimenopause and was organized by Pre-Meeting Co-chair and NAMS Past President, Dr. Cynthia Stuenkel. This symposium addressed the physiology of the menopause transition, contraception, metabolic changes, hot flashes, and reproductive challenges. A report from the 2019 Pre-Meeting Symposium will be published in Menopause during 2020.

New for 2019, NAMS also offered the Menopause 101: Building the Foundation course. Presentations included the pathophysiology of menopause; bone health; cardiovascular health; mood and cognition; nonhormone management for hot flashes; hormone management: oral versus transdermal; and sexual health. The course was a great success with a sell-out crowd.

NAMS presented 13 recognition awards, scholarships, and prizes during the Annual Meeting. These awards acknowledge the diverse and important contributions of our members as well as provide opportunities for those in training to learn more about menopause and midlife women’s health.

The Donor Cocktail Party continued to be a great success and provided a wonderful opportunity for networking and meeting new friends. Thank you to all who attended the event and to all who donated to the Society during 2019.

A major initiative was the publication of the 6th edition of the NAMS textbook, Menopause Practice: A Clinician’s Guide in September 2019. The new textbook was completely updated and the most comprehensive guide for the care of midlife women. It is a must-have resource for those involved in midlife women’s health and research. Dr. Carolyn Crandall served as Editor-in-Chief of the new edition that was written and reviewed by dozens of experts specializing in the care and treatment of midlife women.

NAMS was proud to collaborate with leading medical societies, including the International Menopause Society, the International Society for Sexual Medicine, the Federacion Latinoamericana de Sociedades de Climaterio y Menopausia, the American College of Obstetricians and Gynecologists, the European Menopause and Andropause Society, the International Society for the Study of Women’s Sexual Health, the Royal College of Obstetricians and Gynaecologists, and the Endocrine Society, on the Global Consensus Position Statement on the Use of Testosterone Therapy for Women. The statement was authored by a diverse team of leading experts from around the world and endorsed by other internationally recognized medical societies.

During 2019, NAMS addressed several key issues and shared information with our members to enhance their clinical practices, support their research endeavors, and ultimately improve the lives of the women they serve. Some of these included:

Understanding the frustrations of members in dealing with insurance denials for hormone therapies, NAMS developed three standardized response letters available to download and individualize as needed.

NAMS shared the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendations on the human papillomavirus vaccination.

NAMS addressed the results of the JAMA Network Open study involving the Women’s Health Initiative that shed light on mortality risks of being of normal weight with central obesity.

NAMS commented on the Collaborative Group on Hormonal Factors in Breast Cancer’s report on the timing of hormone therapy and breast cancer risk and indicated that management of menopause symptoms should be individualized, taking into account the severity of the symptoms and a woman’s risk factors, as well as treatment goals and personal preferences.

NAMS supported FDA’s partnership with the National Academy of Sciences, Engineering, and Medicine to study the risks associated with compounded hormone products and continued to advise against the use of compounded bioidentical hormone therapy, given the availability of multiple formulations and doses of FDA-approved bioidentical hormones, specifically estradiol and progesterone.

NAMS continued to work with FDA to remove the black-box warning from local vaginal estrogen therapies and challenged the European Medicines Agency statement on vaginal estradiol creams indicating it would likely result in women’s avoiding a safe, effective, and much-needed treatment for genitourinary syndrome of menopause.

NAMS organized the Workshop on Normal Reference Ranges for Estradiol in Postmenopausal Women in September 2019. The aim of the workshop was to review existing analytical methodologies for measuring estradiol in postmenopausal women and to assess existing data and study cohorts of postmenopausal women for their suitability to establish normal postmenopause reference ranges. The report from the Workshop will be published in Menopause during 2020.

In 2019, Menopause marked its 26th year of publication. Five Menopause articles ranked in the Medscape Top 10 most-frequently read articles by obstetricians and gynecologists for 2019. Menopause also launched a new feature, video summaries of articles prepared by the authors, for subscribers.
Six Practice Pearls on the topics of adnexal masses in menopausal women, clinical care of women with intermediate breast cancer risk, salpingectomy to reduce risk of ovarian cancer in women at average risk, identification and management of urinary incontinence in midlife women, molecular breast imaging, and taking a fresh look at mood, hormones, and menopause. Each Practice Pearl offered members the opportunity to earn continuing education credits.

We continued the successful e-newsletters for our members, including the quarterly Menopause Care Updates, featuring summaries and in-depth commentaries on recent scientific articles chosen to inform and influence current clinical menopause practice. The bimonthly Menopause e-Consult continued to present questions and cases commonly seen in a menopause specialist’s practice, with recognized experts providing their opinions and practice advice.

NAMS Past President, Dr. Marla Shapiro, continued to lead our comprehensive video series for clinicians and women about important midlife health issues. Topics of videos launched during 2019 included:

- New Depression Guidelines
- Hormone Therapy: What Are We Doing in 2019?
- Pharmacologic and Nonpharmacologic Options for Arousal and Orgasm Issues
- GSM Treatment Options for Survivors of Breast Cancer and Those at High Risk of Breast cancer
- The Latest Rap About the Pap: What Clinicians Need to Know
- Sexual Health: Office-based Assessment and Communication Skills
- Midlife Depression

Weight Gain at Menopause
- Bone Density Assessment
- The Role of the Physical Therapist in the Treatment of Female Sexual Dysfunction
- Cardiovascular Update: What Clinicians Need to Know
- Advances in Our Understanding of the Etiology/Mechanisms of Vasomotor Symptoms

The number of NAMS Certified Menopause Practitioners (NCMPs) reached an all-time high during 2019, growing to more than 1,241 healthcare providers.

Our outreach to increase awareness of NAMS as the go-to source for credible information on menopause and midlife women’s health continued. NAMS was featured in high-profile professional and consumer media outlets, including Reader’s Digest, US News and World Report, AARP, ABC News, Prevention, Los Angeles Times, New York Times, Oprah, CNN, and many others.

In June 2019, NAMS was saddened to announce the departure of Dr. JoAnn Pinkerton as she stepped down as NAMS Executive Director. Since 2015, NAMS had been pleased to share Dr. Pinkerton’s time with the University of Virginia.

In July 2019, NAMS was pleased to announce the appointment of Dr. Stephanie Faubion as NAMS Medical Director. Dr. Faubion, a long-time member of NAMS, served on numerous Society committees and on the Board of Trustees.

In September 2019, Dr. Wulf Utian, NAMS Founding Executive Director, announced his retirement from the Board of Trustees. Dr. Utian’s contributions to the organization over the past 30 years are unparalleled, and his guidance, friendship, and wisdom will be missed by all.

To promote the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging.

The NAMS Mission is being fulfilled through the work of dedicated health professionals from multiple disciplines who comprise the membership of the Society. At year-end 2019, our 2,276 members from 41 countries included primarily physicians (71%), with most being obstetricians-gynecologists or reproductive endocrinologists, followed by nurse practitioners (16%) and many other healthcare specialists and research scientists focused on the field of menopause.

NAMS 2019 MEMBERSHIP DEMOGRAPHICS

- Physicians (71%)
- Nurse Practitioners (16%)
- Pharmacists (2%)
- Researchers (2%)
- Other Nurses (7%)
- All Others (7%)
NAMS extends its sincere appreciation to the donors who have generously supported the NAMS Mission. Your contributions have touched the lives of many women. NAMS is a §501(c)(3) nonprofit scientific organization.
Every attempt has been made to accurately list all supporters. Please accept our apologies for any errors or omissions and notify the NAMS Central Office so that we may correct our records.
NAMS Statement of Activities

For the year ended December 31, 2019

<table>
<thead>
<tr>
<th>Revenue and Support</th>
<th>For the year ended December 31, 2019</th>
<th>For the year ended December 31, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership Fees</td>
<td>$599,330</td>
<td>$559,500</td>
</tr>
<tr>
<td>Contributions and Grants</td>
<td>$576,103</td>
<td>$728,068</td>
</tr>
<tr>
<td>Meeting Fees and Exhibits</td>
<td>$1,112,274</td>
<td>$936,922</td>
</tr>
<tr>
<td>Competency Exam Fees</td>
<td>$111,950</td>
<td>$99,475</td>
</tr>
<tr>
<td>Royalty Income</td>
<td>$362,136</td>
<td>$541,094</td>
</tr>
<tr>
<td>Sales of Educational Materials</td>
<td>$114,907</td>
<td>$74,004</td>
</tr>
<tr>
<td>Investment/Interest Income</td>
<td>$186,006</td>
<td>$175,759</td>
</tr>
<tr>
<td>Net Realized and Unrealized Gains/Loss on Investments</td>
<td>$705,173</td>
<td>$(425,075)</td>
</tr>
<tr>
<td>Other</td>
<td>$33,892</td>
<td>$37,263</td>
</tr>
<tr>
<td>Revenue and Support</td>
<td>$3,801,771</td>
<td>$2,727,010</td>
</tr>
</tbody>
</table>

For the year ended December 31, 2018

| Membership Activities     | $185,713                             | $181,201                             |
| Educational Activities    | $1,907,828                           | $1,662,328                           |
| Management and General    | $452,000                             | $497,985                             |
| Fundraising               | $155,062                             | $147,750                             |
| Expenses                  | $2,700,603                           | $2,489,264                           |

This financial information is extracted from the audited financial statements available at the NAMS Central Office.

NAMS Statement of Financial Position

<table>
<thead>
<tr>
<th>December 31, 2019</th>
<th>December 31, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>$1,398,001</td>
</tr>
<tr>
<td>Investments (at fair value)</td>
<td>5,647,191</td>
</tr>
<tr>
<td>Other</td>
<td>63,241</td>
</tr>
<tr>
<td>Assets</td>
<td>$7,108,433</td>
</tr>
<tr>
<td>Liabilities</td>
<td>$320,510</td>
</tr>
<tr>
<td>Net Assets</td>
<td>$6,787,923</td>
</tr>
<tr>
<td>Long-Term Deferred Revenue</td>
<td>60,000</td>
</tr>
<tr>
<td>Total Liabilities and Net Assets</td>
<td>$7,108,433</td>
</tr>
</tbody>
</table>


NAMS Board of Trustees (year-end 2019)

**Officers**

**President**
Rebecca C. Thurston, PhD, University of Pittsburgh, Pittsburgh, Pennsylvania

**President-Elect**
Hadine Joffe, MD, MSc, Harvard Medical School, Boston, Massachusetts

**Treasurer**
Lisa C. Larkin, MD, FACP, NCMP, IF, Lisa Larkin and Associates Internal Medicine and Women’s Health, Cincinnati, Ohio

**Secretary**
Carolyn J. Crandall, MD, MS, FACP, NCMP, FASBMR, David Geffen School of Medicine at University of California, Los Angeles, California

**Immediate Past President**
James H. Liu, MD, NCMP, Case Western Reserve University School of Medicine, Cleveland, Ohio

**Medical Director**
Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF, Mayo Clinic, Rochester, Minnesota

**Members**
Lisa Astalos Chism, DNP, APRN, NCMP, FAANP, Karmanos Cancer Institute, Detroit, Michigan

Samar R. El Khoudary, PhD, MPH, BPharm, FAHA, University of Pittsburgh, Pittsburgh, Pennsylvania

Michael R. McClung, MD, Oregon Osteoporosis Center, Portland, Oregon, and Mary MacKillop Institute for Health Research, Melbourne, Australia

Susan D. Reed, MD, MPH, University of Washington School of Medicine, Seattle, Washington

Nanette F. Santoro, MD, University of Colorado School of Medicine, Aurora, Colorado

Claudio N. Soares, MD, PhD, FRCPC, MBA, Queen’s University School of Medicine, Kingston, Ontario, Canada

**Editor-in-Chief, Menopause**
Isaac Schiff, CM, MD, Harvard Medical School, Boston, Massachusetts

Central Office Staff

Carolyn Develen, Chief Operating Officer
Kathy Method, MA, Communications Manager
Mary Nance, Development Director
Lynne Povhe, Member Services Manager
Elizabeth Slogar, Operations and Finance Manager

The North American Menopause Society (NAMS)
30100 Chagrin Blvd., Suite 210
Pepper Pike, Ohio 44124, USA
T: 440/442-7550 • F: 440/442-2660
Email: info@menopause.org
Website: www.menopause.org

June 2020